Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-30), Nascent Biotech's 9-Day RSI is 55.27.
The industry rank for Nascent Biotech's 9-Day RSI or its related term are showing as below:
NBIO's 9-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 40.575
vs NBIO: 55.27
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Nascent Biotech 9-Day RSI Related Terms
NBIO vs BTAX, PXMD, XSNX: 9-Day RSI Comparison
For the Biotechnology subindustry, Nascent Biotech's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nascent Biotech 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nascent Biotech's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Nascent Biotech's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nascent Biotech (NBIO) has a 9-Day RSI of 55.27 as of Jul. 30, 2026.
Is Nascent Biotech's 9-Day RSI too high?
Nascent Biotech's current 9-Day RSI is 55.27. The Biotechnology industry median 9-Day RSI is 40.58. Nascent Biotech's value of 55.27 is 36.2% above this industry median.
How does Nascent Biotech's 9-Day RSI compare to BTAX and PXMD?
Nascent Biotech's 9-Day RSI of 55.27 can be compared against companies in the Biotechnology industry. The industry median 9-Day RSI is 40.58. Nascent Biotech's value of 55.27 is 36.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 40.58, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nascent Biotech's current 9-Day RSI of 55.27 is 36.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 40.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Biotech's current 9-Day RSI is 55.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current 9-Day RSI of 55.27. The current 9-Day RSI is 55.27 and 36.2% above the Biotechnology industry median of 40.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current 9-Day RSI is 55.27 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NBIO has been successfully added to your 
